neuroendocrine carcinoma

Zevra Therapeutics Publishes Four-Year MIPLYFFA Real-World NPC Data

BOSTON, Aug. 3, 2026 Zevra Therapeutics, Inc. announced the publication of four-year real-world safety and effectiveness data evaluating MIPLYFFA®...

By cGxPwire Editor
August 4, 2026

Bio-Pharma

Rocket Pharmaceuticals Reports Positive RP-A501 Safety Update

CRANBURY, N.J., Aug. 3, 2026 Rocket Pharmaceuticals, Inc. announced a positive clinical safety update from the first three patients...

By cGxPwire Editor
August 4, 2026

Bio-Pharma

Zai Lab Receives FDA Orphan Drug Designation for Zoci

SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...

By cGxPwire Editor
August 4, 2026

Bio-Pharma

IDEAYA Showcases Darovasertib Data at ESMO 2026

SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...

By cGxPwire Editor
July 20, 2026

Pharma

Leads Biolabs Secures Priority Review for Opamtistomig

NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...

By cGxPwire Editor
July 11, 2026

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

Bio-Pharma

SystImmune’s BL-M14D1 Shows Strong Activity in SCLC

REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...

By cGxPwire Editor
June 2, 2026

.Clinical

Leads Biolabs Wins Phase III Approval for Opamtistomig in Advanced EP-NEC

NANJING, China, May 18, 2026 Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) has received approval...